What's New

Medical News
& Alerts

Conferences
& Meetings


Other Medical
Resources

Employment
Opportunities

Partnering
Opportunities

Search results for: Zerit
97%DGNews: Zerit Cleared Under FDA Accelerated Approval Regulations
97%DGNews: Zerit for HIV/AIDS to be Reimbursed by Quebec Government
96%DGNews: Zerit (Stavudine) Once-Daily Extended Release Appears Comparable to Zerit Immediate Release
96%DGNews: Zerit for HIV/AIDS to be Reimbursed by Ontario Government
96%DGNews: Expanded labelling requested for Zerit
96%DGNews: Videx/Zerit Combination Therapy for HIV Radically Reduces Vital Load
95%DGNews: Zerit (stavudine) Approved For First-Line Treatment of HIV in Europe
95%DGNews: ZERIT, an Important New Option for Treating HIV-Infected Children
94%DGNews: FDA Approves Zerit And Videx As First Line HIV Therapy
93%DGNews: Videx Prolongs Lives and Dramatically Delays Progression of AIDS
92%DGNews: ICAAC: Sustiva (Efavirenz) Plus Zerit (Stavudine) And Epivir (Lamivudine) Reduces Viral Load
92%DGNews: FDA Unanimously Recommends Approval of Videx(r) for HIV/AIDS
88%DGNews: Once a Day Combination Therapy Achieves Undetectable HIV Levels
88%DGNews: Agouron Files New Drug Application for Anti-HIV Drug Viracept
87%DGNews: ROI CONFERENCE: Life After Viracept For HIV Patients
86%DGNews: ECCMID: Sustiva Effective In Combination With d4T And 3TC For HIV
86%DGNews: WORLD AIDS CONFERENCE: European Study Suggests d4T/ddI Superiority Over AZT/3TC
85%DGNews: New Two-Drug HIV Therapy Shown to Be Safe, Effective
84%DGNews: ICAAC: Protease Inhibitor-Sparing Regimen Suppresses HIV In Majority Of Patients
83%DGNews: Twice-Daily Viracept Demonstrates Anti-HIV Activity At 48 Weeks
83%DGNews: DRUG RESISTANCE MEETING: Epivir Remains Active Against HIV With Common Resistance Mutation
82%DGNews: ROI CONFERENCE: Patients Respond To Protease Inhibitor Treatment After Viracept Failure
82%DGNews: FDA Approves First Protease Inhibitor Drug for Treatment of HIV
81%DGNews: ROI CONFERENCE: Viracept Therapy Produces Anti-HIV Effects In Women At 12 Months
81%DGNews: Broad-Spectrum Antifungal Licensed by Bristol-Myers Squibb
81%DGNews: FDA Approves Twice-Daily Dosing Of Viracept For HIV
80%DGNews: ECCATH: Atazanavir Demonstrates Antiviral Efficacy, Favorable Lipid Profile
80%DGNews: ROI CONFERENCE: Cellular Concentrations Of Nucleoside Analogues Linked With Viral Load Response
79%DGNews: Efficacy Of Anti-HIV Drug, Viramune (Nevirapine), Confirmed By Experts
76%DGNews: AASLD: HIV Patients Have Liver Damage on Antiretroviral Therapies
75%DGNews: Body Fat Changes Are Not Common in Patients Taking HIV Drugs
74%DGNews: Study On Lipodystrophy Shows Evolving Perceptions By Physicians Treating HIV
71%DGNews: IAS: Viramune (Nevirapine) Combo As Effective As Protease-Inhibitor Combo in Suppressing Human Immunodeficiency Virus
70%DGNews: New Gold Standard for Initial Antiretroviral Treatment of HIV Infection
70%DGNews: ICAAC: Interim Data Show Triple Therapies Are Equivalent In AIDS Patients
Enter keywords you wish to find information about:

Search for documents that contain:
any of these words.
this exact phrase.
all of these words.

 

 

This site is maintained by webmaster@pslgroup.com
Please contact us with any comments, problems or bugs.

All contents Copyright (c) 1998 PSL Consulting Group Inc.
all rights reserved.